Developing The Pharmaceutical Guided Missile To Defeat Coronavirus Lung Infections

+ Market Ready CBD Derma Cosmetic Brand And Patent-Pending CBD Pain Relief Brand

Sponsored
Message: WEEKEND FEATURE: Innocan Pharma (INNO:CSE) Developing The Pharmaceutical Guided Missile To Defeat Coronavirus Lung Infections

WEEKEND FEATURE: Innocan Pharma (INNO:CSE) Developing The Pharmaceutical Guided Missile To Defeat Coronavirus Lung Infections

posted on Oct 16, 2020 05:46PM

(INNO:CSE)

Innocan Pharma Is A Pharmaceutical Company That Specializes In The Development Of New Drug Platforms Which Combine Unique Properties of Cannabinoids.

WHY INNOCAN?

Innocan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

PHARMACEUTICAL

CLX - THE GUIDED MISSILE

  • Revolutionary Technology Targeting Lungs Infected  With Coronavirus or other viral infections 
    • Done By Combining CBD with Stem Cell Particles (Exosomes)
    • Research & Licensing Agreement with Tel Aviv University
  • Developing CLX, The Ballistic Missile Of Coronavirus Lung Infections

LPT – SEPARATE BREAKTHROUGH DELIVERLY AND CONTROL RELEASE TECHNOLOGY THAT ENABLES INJECTION OF CBD

Major Milestone Achieved in Developing Its Unique CBD-Loaded Liposome Platform Technology for Injectable CBD

  • Study on mice demonstrated a prolonged release of Cannabidiol into the blood for at least three weeks after one administration
  • Conducted based on Innocan’s licensed CBD loaded liposome platform technology for injectable CBD
  • Conducted on over 35 mice and found significant amounts of CBD in the mice’s blood 21 days after they were injected with a single injection of liposomal CBD using Innocan’s CBD loaded LPT
  • Results are substantial when comparing the oral or smoking administration of CBD, in which CBD was found in the blood of mice only for a period of up to 36 hours after one administration
  • Results open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of the formulations.

CONSUMER RETAIL – DERMA COSMETICS 

  • A Premium Derma Cosmetics Brand
  • Containing Highly Concentrated Ingredients Formulated with CBD
  • Manufacturing & Supply Agreements - Europe and United States
  • Manufacturing Has Commenced For 9 Products
  • Distribution Agreements In Place
  • Completed Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) CBD Premium Facial Serum on Skin Hydration Watch Video
  • Cosmetic Clinical Study On 20 Volunteers Presented A 90 – 95% Facial Skin Wrinkle Reduction Read More

The following are the results of the application of the SHIR - Innocan Pharma Facial Serum with 300 mg of Cannabidiol after 28 days of using the serum twice a day:

The percentage of the subjects The subjects considered after using the SHIR™ Premium Facial Serum for 28 days
90% The skin with less wrinkles
95% With finer expression lines
100% The anti-wrinkles effect is the most appreciated product's effect
90% A more even skin tone
80% A depigmenting effect
85% The skin was more moisturized
90% Evaluated the product as good to very good

 

CBD+

Premium Collection created with a triple dose of pure 300mg CBD and an Anti-aging complex designed to retain the skins elasticity, strength, and firmness for natural radiance.

CBD MUST

Formulated with highly effective pure 100mg CBD and effective ingredients designed to nourish and hydrate the skin for a natural glow.

 

OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF 

  • Patent-Pending CBD Pain Relief Brand
  • Versions Include Spray, Roll-On and Cream
  • Relief & Go Spray – First Product Being Manufactured
    • FDA Technical Validation
    • FDA Approval To Commence Marketing In The United States
  •   Manufacturing Commencement
    • New Jersey (United States Market)
    • Portugal (Asia and Europe Markets)
  • Sales Commenced

     SUPERIOR MANAGEMENT TEAM

  • The Innocan Leadership Group Is Incomparable In The Small Cap World
  • Comprised Of Leading Israeli Pharmaceutical Executives
  • Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
  • Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
  • Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
  • Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.
  • Together they have built a formidable team at Innocan

FULL DISCLOSURE: Innocan Pharma is an advertising client of AGORA Internet Relations Corp.

Share
New Message
Please login to post a reply